TNFRSF4 Protein (His tag)
-
- Target Alle TNFRSF4 Proteine anzeigen
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
- Protein-Typ
- Recombinant
- Biologische Aktivität
- Active
-
Spezies
- Human
-
Quelle
- HEK-293 Cells
- Aufreinigungstag / Konjugat
- Dieses TNFRSF4 Protein ist gelabelt mit His tag.
- Applikation
- Western Blotting (WB), ELISA
- Produktmerkmale
-
Measured by its binding ability in a functional ELISA. Immobilized rh TNFRSF4 / OX40 / CD134 at 2 μg/mL (100 μL/well) can bind human TNFSF4 Fc Chimera, The EC50 of human TNFSF4 Fc Chimera is 30 ng/mL.
- Reinheit
- >92 % as determined by SDS-PAGE.
- Top Product
- Discover our top product TNFRSF4 Protein
-
-
- Applikationshinweise
- This recombinant protein can be used for WB, ELISA. For research use only.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Buffer
- PBS, pH 7.4
- Lagerung
- -80 °C,-20 °C
- Informationen zur Lagerung
- Lyophilized Protein should be stored at -20°C or lower for long term storage. Upon reconstitution, working aliquots should be stored at -20°C or -70°C. Avoid repeated freeze-thaw cycles.
-
- Target
- TNFRSF4 (Tumor Necrosis Factor Receptor Superfamily, Member 4 (TNFRSF4))
- Andere Bezeichnung
- CD134 (TNFRSF4 Produkte)
- Synonyme
- TNFRSF4 Protein, ACT35 Protein, CD134 Protein, Ly-70 Protein, Ox40 Protein, TXGP1L Protein, Txgp1 Protein, OX40 Protein, TNF receptor superfamily member 4 Protein, tumor necrosis factor receptor superfamily, member 4 Protein, TNFRSF4 Protein, Tnfrsf4 Protein
- Hintergrund
- Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.
- Molekulargewicht
- 21 kDa
- Gen-ID
- 7293
- NCBI Accession
- NP_003318
- UniProt
- P43489
- Pathways
- Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
-